MedTrace Logo

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

NCT02873325 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2018-02-01

No results posted yet for this study

Summary

DESIGN:

Disease registry - non-interventional.

INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

Conditions

  • Infectious Complications Following HSCT

Interventions

OTHER

antiviral therapies for CMV and/or ADV

salvage antiviral treatments for ADV and/or CMV

Sponsors & Collaborators

  • Cell Medica Ltd

    lead INDUSTRY

Principal Investigators

  • Prashant Hiwarkar · Birmingham Children's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-11
Primary Completion
2017-02-23
Completion
2017-02-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873325 on ClinicalTrials.gov